COVID-19 Vaccine Booster Uptake and Effectiveness Among Persons With Systemic Autoimmune and Rheumatic Diseases
Authors' conclusion
COVID-19 booster vaccinations provided significant protection against severe COVID-19 in persons with SARDs.
Study context
- Population
- Adults with systemic autoimmune and rheumatic diseases (SARDs) receiving DMARDs at 4 US health systemstwo cohorts: 201,165 and 246,991
- Exposure
- COVID-19 booster vs no booster
- Monovalent boostern = 126,756
- Bivalent vaccinen = 87,906
- Outcome
- COVID-19 hospitalization (VE of booster)
Methodological detailsmulticentre (4 health systems)
- Multicentre (4 health systems)
Main finding
As reported in the abstract
COVID-19 hospitalization, monovalent booster period · follow-up to August 31, 2022
Adjusted vaccine effectiveness (VE)
38%
95% CI 31–44%
By group
Observational data: associations, not effects.
Further findings
Rate, per 1000 person-years (PY)
| Outcome | Bivalent vaccine | No bivalent vaccine | Adjusted VE (95% CI) |
|---|---|---|---|
| COVID-19 hospitalization, bivalent vaccine period · September 1, 2022 to August 31, 2023Bivalent vaccine vs No bivalent vaccine · number needed to vaccinate 617 (95% CI 500-838) | 7.9 | 10.2 | 32% (24–39%) |
- COVID-19 hospitalization, bivalent vaccine period: 233,622 PY of follow-up
Original publication
COVID-19 Vaccine Booster Uptake and Effectiveness Among Persons With Systemic Autoimmune and Rheumatic Diseases. J Rheumatol. Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →